[Molecular Tumour Boards for Urological Tumours: Hope or Disappointment?].
Aktuelle Urol 2026; 57(1): 96-101;
Gaisa NT, Eckstein M, Casuscelli J, Kalogirou C, Zschäbitz S, Dörffer N, Reis H

Low-intensity shockwave therapy for erectile dysfunction due to diabetes mellitus or coronary artery disease: An individual participant data meta-analysis from a single center.
Andrology 2026; 14(2): 348-351;
Pyrgidis N, Kalyvianakis D, Mykoniatis I, Hatzichristou D

Deep early tumour shrinkage in metastatic upper tract urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab.
BJU Int 2026;
Semmler M, Heimer M, Aydogdu C, Enzinger B, Brinkmann I, Kolligs F, Schulz GB, Stief CG, Kazmierczak PM, Casuscelli J, Eismann L

Response to "Comment on 'Peri-operative outcomes of open, laparoscopic and robotic simple prostatectomy'".
BJU Int 2026; 137(3)
Pyrgidis N, Weinhold P, Schulz GB, Atzler M, Stadelmeier LF, Papadopoulos I, Stief C, Marcon J, Keller P

Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
BJU Int 2026; 137(2): 323-331;
Pellegrino F, de Angelis M, Scilipoti P, Longoni M, Subiela JD, Contieri R, Afferi L, Zamboni S, Suardi N, Musi G, Luzzago S, D'Andrea D, Laukhtina E, Soria F, Gontero P, Del Giudice F, Fallara G, Roupret M, Grobet-Jeandin E, Baudewyns A, Tanaka H, Matsumoto S, Fujii Y, Proietti F, Simone G, Schulz GB, Pyrgidis N, Ploussard G, Antonelli A, Bertolo R, Roumiguie M, Bajeot AS, Resca S, Beatrici E, Lambert E, Mottrie A, Mir MC, Umari P, Teoh J, Wong C, Mertens LS, Pichler R, Mori K, Ślusarczyk A, Poyet C, Albisinni S, Aziz A, Volpe A, Shariat S, Pradere B, Karakiewicz P, Necchi A, Ferro M, Montorsi F, Briganti A, Moschini M, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU‐YAU)

Radiosurgery in Upper Tract Urothelial Carcinoma (UTUC).
Cancers (Basel) 2026; 18(6)
Staehler M, Blajan I, Aydogdu C, Graser A, Hoffmann M, Brinkmann I, Schulz GB, Yen A, Cheng JJ, Fürweger C, Psutka SP, Hannan R, Muacevic A

Clinical Management of Synchronous and Metachronous Renal Lesions in Patients With Oncocytoma Treated With Nephrectomy: A 30-Year Single-Center Experience.
Clin Genitourin Cancer 2026; 24(1)
Eismann L, Reese SW, Dawidek MT, Calderon LP, Aulitzky A, Vazquez-Rivera K, Coleman JA, Stief CG, Reznik E, Russo P, Hakimi AA

A comparison between hyperspectral imaging and RGB-based tissue perfusion assessment of human skin using convolutional neural networks.
Comput Biol Med 2026;
Linek M, Schrader I, Strauß K, Volgger V, Rühm A, Sroka R, Aumiller M

PET-based risk stratification for adverse events under [225Ac]Ac-PSMA radioligand therapy.
Eur J Nucl Med Mol Imaging 2026;
Widjaja L, Siegmund SC, Gildehaus FJ, Schmidt-Hegemann NS, Pomper MG, Rowe SP, Bundschuh RA, Wenter V, Sheikh GT, Klimek K, Stief CG, Zacherl MJ, Werner RA, Casuscelli J

Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis.
Eur J Nucl Med Mol Imaging 2026; 53(5): 3162-3171;
Pabst KM, Siegmund SC, Holzgreve A, Schmid HP, Bartel T, Herrmann K, Küper AT, Aydogdu C, Kersting D, Kesch C, Hadaschik BA, Unterrainer M, Stief CG, Cyran CC, Werner RA, Fendler WP, Casuscelli J, Unterrainer LM

Refining the clinical utility of [177Lu]Lu/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer.
Eur J Nucl Med Mol Imaging 2026; 53(4): 2271-2281;
Widjaja L, Hornfeck J, Siegmund SC, Gildehaus FJ, Schmidt-Hegemann NS, Wenter V, Sheikh GT, Klimek K, Casuscelli J, Stief CG, Zacherl MJ, Werner RA

Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [225Ac]Ac/[177Lu]Lu-PSMA-therapy.
Eur J Nucl Med Mol Imaging 2026;
Sheikh GT, Siegmund SC, Widjaja L, Takayama Fouladgar SL, Delker A, Casuscelli J, Unterrainer LM, Werner RA, Zacherl MJ

[177Lu]Lu-PSMA radioligand therapy in younger prostate cancer patients: A matched-pair analysis between patients ≤ 65 and ≥ 70 years old.
Eur J Nucl Med Mol Imaging 2026;
Hornfeck J, Dahlmann PJ, Siegmund SC, Gildehaus FJ, Delker A, Schmidt-Hegemann NS, Bundschuh RA, Zacherl MJ, Klimek K, Casuscelli J, Stief CG, Werner RA, Widjaja L

Re: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.
Eur Urol 2026; 89(1): 96-97;
Brookman-May SD, Kempin S, Enzinger B

Gender Disparities in Health-related Quality of Life Outcomes Following Radical Cystectomy for Bladder Cancer.
Eur Urol Focus 2026; 12(2): 182-191;
Westhofen T, Eismann L, Schulz GB, Bauer RM, Waidelich R, Casuscelli J, Berg E, Blajan I, Götz M, Brinkmann I, Coleman J, Shahbaz-Stöcker W, Mehrens D, Buchner A, Karl A, Schlenker B, Becker A, Stief CG, Rodler S, Kretschmer A

The Role of Salvage Cystectomy After Prior Trimodality Therapy: A Multinational Match-paired Analysis.
Eur Urol Focus 2026; 12(1): 88-95;
Pyrgidis N, Schulz GB, Scilipoti P, Pellegrino F, Casuscelli J, Tzelves L, Katsimperis S, Ciavarella D, Mir MC, Sokolakis I, Klatte T, Belinchon AR, Velasco JC, Fujii Y, Tanaka H, Yoshida S, Matsumoto S, Umari P, Teoh JY, Ming CWH, Simone G, Mastroianni R, Mayr R, Giudice FD, Moschini M

Prospective Evaluation of Blood-based and Microbiological Early Indicators of In-hospital Infectious Complications After Open CystectomyEur. Urol. Open Sci. 2026; 83(): 1-8;
Ebner B, Hirsch J, Holz A, Eismann L, Hermans J, Pyrgidis N, Kidess M, Semmler M, Brinkmann I, Aydogdu C, Chaloupka M, Apfelbeck M, Lindner AK, Weinhold P, Stief CG, Volz Y, Schulz GB

High-Grade Urothelial Carcinoma Arising From a Ureteral Diverticulum: A Rare Case Report.
IJU Case Rep 2026; 9(2)
Papadopoulos I, Ledderose S, Ebner B, Berg E, Aydogdu C, Marcon J, Bischoff R, Kazmierczak P, Stief CG, Eismann L

Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.
Int J Cancer 2026; 158(6): 1690-1702;
Goebell PJ, Bögemann M, Nusch A, Grünwald V, Müller L, von der Heyde E, Martens UM, Lennartz C, Koska M, Potthoff K, Kaiser-Osterhues A, Grüllich C, Staehler M, Jänicke M, Marschner D, CARAT Registry Group

Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.
Int J Cancer 2026; 158(9): 2440-2451;
Dinkel H, Materna L, Stelmach R, Zschäbitz S, Neuberger S, Aydogdu CD, Casuscelli J, Egenolf T, Silberg M, Steinestel J, Strauss A, Kirchhoff F, Ahrens M, Paffenholz P, Cathomas R, Özdemir BC, Gossler C, Ivanyi P, Rehlinghaus M, Hilser T, Grünwald V, Schlack K

PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [225Ac]Ac-PSMA Radiopharmaceutical Therapy.
J Nucl Med 2026; 67(4): 568-575;
Widjaja L, Siegmund SC, Gildehaus FJ, Delker A, Schmidt-Hegemann NS, Pomper MG, Rowe SP, Bundschuh RA, Wenter V, Sheikh GT, Klimek K, Casuscelli J, Stief C, Zacherl MJ, Werner RA

PSMA PET-Positive Local Recurrences in the Prostate Bed Region and Their Coverage Based on Clinical Target Volume Delineation Guidelines from ESTRO-ACROP, PERYTON, FROGG, GFRU, and RTOG.
J Nucl Med 2026; 67(3): 404-409;
Moar EF, Keilholz M, Sheikh GT, Werner RA, Trapp C, Casuscelli J, Chaloupka M, Kunz WG, Kazmierczak P, Widjaja L, Brose SF, Eze C, Walter F, Belka C, Li M, Rogowski P, Schmidt-Hegemann NS

Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [177Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics.
J Nucl Med 2026;
Widjaja L, Hornfeck J, Siegmund SC, Gildehaus FJ, Delker A, Schmidt-Hegemann NS, Rowe SP, Casuscelli J, Stief C, Zacherl MJ, Klimek K, Werner RA

Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma.
J Nucl Med 2026;
Novruzov E, Mamlins E, Widjaja L, Siegmund SC, Watabe T, Mori Y, Stief C, Tufman A, Herrmann K, Gorin MA, Pomper MG, Rowe SP, Giesel FL, Werner RA, Sheikh GT

Target and off-target effects of vibegron on smooth muscle contraction of human detrusor and prostate tissues.
Naunyn Schmiedebergs Arch Pharmacol 2026; 399(4): 5463-5481;
Hu S, Xu Y, Brandstetter M, Tamalunas A, Kale OE, Keller P, Stadelmeier LF, Weinhold P, Stief CG, Hennenberg M

Adjustable TransObturator Male System (ATOMS) After Desobstructive Surgery for Benign Prostatic Hyperplasia - Does the Type of Desobstructive Surgery Make a Difference?
Neurourol Urodyn 2026; 45(2): 372-378;
Stadelmeier LF, Lederer E, Heimke F, Kidess M, Pyrgidis N, Georgieva T, Hermans J, Hoffmann M, Ebner B, Tamalunas A, Keller P, Chaloupka M, Bauer R, Marcon J, Weinhold P, Stief CG, Volz Y

Open vs. Robotic Radical Prostatectomy: Impact on Adjustable Transobturator Male Sling (ATOMS) Outcomes for the Treatment of Stress Urinary Incontinence.
Neurourol Urodyn 2026;
Kidess M, Lederer E, Georgieva T, Hermans J, Stadelmeier L, Happe M, Pyrgidis N, Keller P, Marcon J, Weinhold P, Chaloupka M, Ebner B, Bauer R, Stief CG, Volz Y

Voiding symptoms aggravate with decreasing stromal/epithelial ratio and increasing glandular-epithelial content in patients undergoing laser enucleation for benign prostatic hyperplasia, independently from prostate size.
PLoS ONE 2026; 21(3)
Keller P, Hu S, Zhu W, Xu Y, Berger L, Nicola P, Weinhold P, Tamalunas A, Stief CG, Hennenberg M

European survey on laser safety management in medical settings.
Phys Med 2026;
Clarke S, Biondi M, Manivannan A, Koutsouveli E, Wilén J, Banahan C, Ivanova M, Gómez-Varela AI, Verdaasdonk R, Tornero J, Sroka R, Vella N, Springer A

Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study.
Prostate Cancer Prostatic Dis 2026; 29(1): 138-143;
Pyrgidis N, Schulz GB, Weinhold P, Atzler M, Stadelmeier LF, Papadopoulos I, Stief C, Marcon J, Keller P

Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells.
Sci Rep 2026; 16(1)
Kabus M, Aumiller M, Rühm A, Pongratz T, Hoffmann MJ, Buchner A, Sroka R, Pohla H

Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study.
Urol Int 2026; (): 1-10;
Aydogdu C, Urban F, Berg E, Götz M, Rodler S, Brinkmann I, Enzinger B, Semmler M, Kolligs F, Hoffmann M, Stadelmeier LF, Westhofen T, Unterrainer LM, Heinemann V, Stief CG, Tamalunas A, Casuscelli J

Real-World Insights: Balancing Diagnostic Benefits and Oncological Risks of Ureteroscopic Biopsy before Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
Urol Int 2026; 110(2): 145-153;
Bohn L, Nofal M, Ledderose S, Schulz GB, Bischoff R, Kazmierczak PM, Chaloupka M, Casuscelli J, Waidelich R, Stief CG, Rodler S, Eismann L, Ebner B

Determinants of treatment pathway in renal colic: a size-stratified analysis from the emergency department of a tertiary center.
Urolithiasis 2026; 54(1)
Blajan I, Ebner B, Volz Y, Klein M, Stief CG, Apfelbeck M, Chaloupka M

[Pharmacotherapy of benign prostatic syndrome : Medications, innovations and future prospects].
Urologie 2026; 65(4): 429-437;
Keller P, Tamalunas A, Atzler M, Kidess M, Stadelmeier L, Pyrgidis N, Hennenberg M, Stief CG, Weinhold P

Functional outcome and quality of life (QoL) in patients undergoing radical prostatectomy without prior prostate biopsy.
World J Urol 2026; 44(1)
Cao Y, Berg E, Kazmierczak PM, Stief CG, Buchner A